PT -期刊文章盟约书亚·m·科恩AU -克里斯汀Bibeau盟Maja冷冻AU -迈克尔·j·Seminerio盟Verena拉米雷斯Campos AU -辛格Rashmi b . Halker盟杰西卡Ailani TI -逆转慢性偏头痛患者的情景与Fremanezumab治疗偏头痛的分类(P4.112) DP - 2018年4月10 TA -神经病学PG - P4.112 VI - 90 IP - 15补充4099 - //www.ez-admanager.com/content/90/15_Supplement/P4.112.short 4100 - //www.ez-admanager.com/content/90/15_Supplem首页ent/P4.112.full所以Neurology2018 4月10;90 AB -目的:评估fremanezumab对降级的影响从慢性偏头痛(CM)、情景性偏头痛(EM)。背景:厘米和EM临床、功能和结构上有区别,证据表明他们可能是独立的条件。此外,患者CM通常并存状况有更多和更频繁的药物过度使用,这使他们的临床管理。Fremanezumab (tev - 48125),一个全人源化单克隆抗体针对降钙素相关基因肽(CGRP怎样),展示了在偏头痛的预防功效。设计/方法:在这第三阶段,多中心、随机、双盲、安慰剂对照,与这些相应平行的组织学习,成年人与前瞻性证实厘米(≥15天头痛和偏头痛≥8天/月)被随机分配比皮下注射fremanezumab季度(675毫克基线;安慰剂在周4和8),每月fremanezumab(675毫克基线;在周4和8)225毫克,或匹配的安慰剂在12周的治疗期。事后分析评估病人恢复的比例从CM EM,定义为患者头痛≥15天/月在基线(28天预处理段),然后& lt;每月15天头痛在所有三个月的治疗期。结果:1130厘米的分析患者随机在这个试验(季度,N = 376;每月,N = 379; placebo, N=375), significantly more fremanezumab-treated patients reverted from having ≥15 headache days per month at baseline to <15 headache days per month in Months 1, 2, and 3 (quarterly: 121 patients [32%]; monthly: 133 patients [35%]) than those who received placebo (86 patients [23%]; both, P≤0.002). On average, these fremanezumab-treated patients had 18–19 headache days per month at baseline and showed reductions to 6–9 headache days during any month in the treatment period, representing up to an approximately 70% reduction in headache days.Conclusions: Along with its efficacy as a migraine preventive treatment, fremanezumab demonstrated the potential benefit for reversion from CM to EM.Study Supported by:This study was funded by Teva Pharmaceutical Industries, Petach Tikva, Israel.Disclosure: Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Bibeau has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries. Dr. Galic has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Seminerio has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Ramirez Campos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Halker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, MedLink. Dr. Halker has received personal compensation in an editorial capacity for Current Neurology and Neuroscience Reports. Dr. Ailani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Avanir, Eli Lilly, Teva Pharmaceuticals, Promius. Dr. Ailani has received personal compensation in an editorial capacity for Current Pain and Headache Reports. Dr. Ailani has received research support from Theranica.